“Acriptega” (dolutegravir/lamivudine/tenofovir disoproxil fumarate)
฿2,900 — available for auto-ship subscription
Acriptega is a single-tablet antiretroviral regimen designed for effective treatment of HIV-1 infection.
This medication combines three potent antiretroviral agents that work synergistically to suppress HIV viral replication, enabling individuals to achieve and maintain an undetectable viral load.
Acriptega offers efficacy, ease of use, and a strong safety profile, making it suitable both as initial therapy and for patients transitioning from other regimens.
Indications
- Treatment of HIV-1 infection in adults and adolescents weighing ≥30 kg.
- Recommended as a first-line HIV treatment or for those switching from other antiretroviral therapies.
Benefits
- Powerful Viral Suppression: Effectively maintains undetectable viral load (<50 copies/mL), preventing HIV transmission (Undetectable = Untransmittable, U=U).
- Convenience & Improved Adherence: Single tablet regimen taken once daily significantly reduces pill burden, promoting adherence.
- Robust Safety Profile: Demonstrates a favorable safety and tolerability profile, with fewer side effects compared to older HIV treatment regimens.
- Minimal Drug Interactions: Designed to be safely used alongside most common medications, minimizing complex dosage adjustments.
- Proven Effectiveness: Clinical studies demonstrate strong long-term efficacy and patient tolerability, supporting sustained viral suppression.
Acriptega (Manufactured by Mylan) is globally recognized for its affordability, effectiveness, and patient-friendly regimen, positioning it as an important treatment option in the management of HIV-1 infection, particularly in resource-limited settings.
